ClinicalTrials.gg
CompletedNCT06698198Updated Nov 20, 2024

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

A Phase 1 interventional study of Pneumococcal Conjugate Vaccine and Prevnar 13® in Pneumococcal Immunization, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 2 sites in United States. Open to participants aged 19 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 1 month ago, and no results have been posted to the registry.
  • Registered 5 years 11 months after the study started (first participant enrolled Dec 2018, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
19 Years to 49 Years
Sex
All
01

Study summary

This was a Phase I, randomized, active-controlled, observer-blinded, multi-center study to assess the safety and the immunogenicity of 4 Pneumococcal Conjugate Vaccines (PCV) candidates in parallel with Prevnar 13, in Healthy Adults (19-49 years) in the United States.

02

Conditions studied

  • Pneumococcal Immunization
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 19 to 49 years on the day of inclusion ("19 to 49 years" means from the day of the 19th birthday to the day before the 50th birthday)
  • Form (ICF) has been signed and dated
  • Able to attend all scheduled visits and to comply with all trial procedures
  • within the range of 18.5 and 29.9 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant, or lactating, or of and not using an effective method of or abstinence from at least 4 weeks prior to vaccine injection until at least 4 weeks after injection. To be considered of non-childbearing potential, a female must be pre-menarche, or for at least 1 year, or surgically sterile.
  • Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following trial injection, except for influenza vaccination, which may be received at least 2 weeks before SP0202 or Prevnar 13 injection.
  • Previous vaccination against S. pneumoniae with either a pneumococcal conjugate vaccine (PCV) or a Pneumococcal polysaccharide vaccines (PPSV).
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Group 1: Pneumococcal Conjugate Vaccine (PCV) SP0202-I

    Participants will receive 1 intramuscular injection of PCV formulation SP0202-I

    Biological: Pneumococcal Conjugate Vaccine

  • Experimental
    Group 2: Pneumococcal Conjugate Vaccine (PCV) SP0202-II

    Participants will receive 1 intramuscular injection of PCV formulation SP0202-II

    Biological: Pneumococcal Conjugate Vaccine

  • Experimental
    Group 3: Pneumococcal Conjugate Vaccine (PCV) SP0202-III

    Participants will receive 1 intramuscular injection of PCV formulation SP0202-III

    Biological: Pneumococcal Conjugate Vaccine

  • Experimental
    Group 4: Pneumococcal Conjugate Vaccine (PCV) SP0202-IV

    Participants will receive 1 intramuscular injection of PCV formulation SP0202-IV

    Biological: Pneumococcal Conjugate Vaccine

  • Active comparator
    Group 5: Prevnar 13®

    Biological: Prevnar 13®

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of unsolicited systemic AEs reported in the 30 minutes after injection

    Occurrence of any unsolicited (spontaneously reported) systemic Adverse Events (AEs) reported in the 30 minutes after injection of a SP0202 formulation or Prevnar 13.

    Time frame: Up to 30 minutes post-vaccination

  2. Occurrence of solicited injection site and systemic reactions

    Number of participants reporting solicited injection site reactions (pain, redness, swelling) and solicited systemic reactions (pyrexia, headache, malaise, myalgia, arthralgia, chills)

    Time frame: Up to 7 days post-vaccination

  3. Occurrence of unsolicited (spontaneously reported) AEs up to 30 days after injection

    Occurrence of unsolicited (spontaneously reported) Adverse Events (AEs) up to 30 days after injection of a SP0202 formulation or Prevnar 13.

    Time frame: Up to 30 days after vaccination

  4. Serotype-specific immunoglobulin type G (IgG) concentrations

    Geometric Mean (GM) of serotype-specific IgG concentrations for all pneumococcal serotypes included in the Pneumococcal Conjugate Vaccine (PCV) formulations, as measured by electro-chemiluminescence (ECL) assay

    Time frame: Up to 30 days after vaccination

  5. Serotype-specific opsonophagocytic activity (OPA) titers

    GM of serotype-specific OPA titers for all pneumococcal serotypes included in the Pneumococcal Conjugate Vaccine (PCV) formulations, as determined by multiplex opsonophagocytic assay (MOPA)

    Time frame: Up to 30 days after vaccination

Secondary outcomes

  1. Serotype-specific IgG concentrations ratio (post/pre-vaccination)

    GM of serotype-specific IgG concentrations ratio (post-/pre-vaccination) for each pneumococcal serotypes included in the Pneumococcal Conjugate Vaccine (PCV) formulations, as measured by ECL assay

    Time frame: Up to 30 days after vaccination

  2. ≥ 4-fold serotype-specific IgG concentrations increase

    Percentage of participants with ≥ 4-fold serotype-specific IgG concentrations increase from baseline to 1 month post-vaccination for each pneumococcal serotypes included in the Pneumococcal Conjugate Vaccine (PCV) formulations, as measured by ECL

    Time frame: Up to 30 days after vaccination

  3. Serotype-specific OPA titers ratio (post/pre-vaccination)

    GM of serotype-specific OPA titers ratio (post-/pre-vaccination) for each pneumococcal serotypes included in the Pneumococcal Conjugate Vaccine (PCV) formulations, as determined by MOPA

    Time frame: Up to 30 days after vaccination

  4. ≥ 4-fold serotype-specific OPA titers increase

    Percentage of participants with ≥ 4-fold serotype-specific IgG concentrations increase from baseline to post-vaccination for each pneumococcal serotypes included in the Pneumococcal Conjugate Vaccine (PCV) formulations, as determined by MOPA

    Time frame: Up to 30 days after vaccination

07

Study locations

2 sites
  • Investigational Site Number: 0002
    Metairie, Louisiana 70427, United States
  • Investigational Site Number: 0001
    Newark, New Jersey 07103, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Sep 2019, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartActual
Dec 3, 2018
Primary completionActual
Sep 30, 2019
CompletionActual
Sep 30, 2019
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06698198
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
Dec 3, 2018
Primary completion
Sep 30, 2019
Completion
Sep 30, 2019
Last update
Nov 20, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal Conjugate Vaccine

Start the discussion